July 15th 2025
Relacorilant plus nab-paclitaxel led to a median PFS and OS of 6.54 months and 15.97 months, respectively, in patients with platinum-resistant ovarian cancer.
Individualized Starting Dose of Maintenance Niraparib Increases PFS vs Placebo in Ovarian Cancer
March 20th 2022The phase 3 PRIME study showed increased progression-free survival for patients with newly diagnosed ovarian cancer who were treated with an individualized starting dose of maintenance niraparib vs placebo.
Early Activity of Neoadjuvant Niraparib in HRD+ Ovarian Cancer Reported in NANT Trial
March 19th 2022Patients with BRCA-mutant, homologous repair deficiency–positive advanced resectable ovarian cancer may benefit from treatment with neoadjuvant niraparib, according to early results of a phase 2 trial reported at 2022 SGO.
Long-Term PFS Benefit With Olaparib in nonBRCA-Mutant Ovarian Cancer More Likely With HRD Positivity
March 18th 2022Long-term progression-free survival was associated with various clinical and molecular factors in patients receiving olaparib who had platinum-sensitive relapsed ovarian cancer and no germline mutations in BRCA1/2.